Acyclovir (ACV)

DRUG3 trials

Sponsors

French National Agency for Research on AIDS and Viral Hepatitis, Merck Sharp & Dohme LLC, University of Sao Paulo General Hospital

Conditions

Autoimmune Rheumatic DiseasesCMV DiseaseHerpes GenitalisPreventionRecurrent Herpes SimplexUlcer

Phase 2

Anti-Herpetic Treatment of Genital Ulcer : Effect on HIV & Herpes Shedding (ANRS 1212)

CompletedNCT00158483

French National Agency for Research on AIDS and Viral HepatitisHerpes Genitalis, Ulcer

Start: 2003-05-31End: 2005-10-31Updated: 2008-12-30

Phase 3

Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002)

CompletedNCT03443869

Merck Sharp & Dohme LLCCMV Disease

Start: 2018-05-03End: 2022-04-05Updated: 2023-07-28

Phase 4

Prevention of Recurrence of Herpes Simplex in Autoimmune Rheumatic Diseases

RecruitingNCT07341386

University of Sao Paulo General HospitalAutoimmune Rheumatic Diseases, Prevention, Recurrent Herpes Simplex

Start: 2026-06-25End: 2028-04-01Target: 62Updated: 2026-08-05

Related Papers

Favorable Adherence and Tolerability of Letermovir Versus Valganciclovir for Cytomegalovirus Prophylaxis in Kidney Transplant Recipients Aged 65 y or Older: Findings From a Randomized, Phase 3 Trial

Transplantation Direct2026-08-21

Cytomegalovirus-Specific Cell-Mediated Immunity for Prediction of Postprophylaxis CMV Disease in a Phase 3 Trial of Letermovir Versus Valganciclovir Prophylaxis in Donor CMV-Seropositive/Recipient CMV-Seronegative Kidney Transplant Recipients

Clinical Infectious Diseases2025-11-181 citations

Impact of kidney function on 200 days of antiviral prophylaxis for cytomegalovirus disease in cytomegalovirus-seronegative recipients of cytomegalovirus-seropositive donor kidneys: Post hoc analysis of a randomized, phase 3 trial of letermovir vs valganciclovir prophylaxis.

2025-07-212 citations

Cytomegalovirus Antiviral Resistance Among Kidney Transplant Recipients in a Phase 3 Trial of Letermovir vs Valganciclovir Prophylaxis

The Journal of Infectious Diseases2024-06-104 citations

Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients

JAMA2023-06-07163 citations

LB2307. Safety and Efficacy of Letermovir (LET) versus Valganciclovir (VGCV) for Prevention of Cytomegalovirus (CMV) Disease in Kidney Transplant Recipients (KTRs): A Phase 3 Randomized Study

Open Forum Infectious Diseases2022-12-018 citations

Impact of acyclovir on genital and plasma HIV-1 RNA, genital herpes simplex virus type 2 DNA, and ulcer healing among HIV-1-infected African women with herpes ulcers: a randomized placebo-controlled trial.

2009-07-0127 citations